18.49
1.58 (9.34%)
| Penutupan Terdahulu | 16.91 |
| Buka | 16.92 |
| Jumlah Dagangan | 1,860,359 |
| Purata Dagangan (3B) | 3,093,068 |
| Modal Pasaran | 839,560,640 |
| Harga / Jualan (P/S) | 18.04 |
| Harga / Buku (P/B) | 7.80 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 13 Nov 2024 |
| Margin Keuntungan | -146.86% |
| Margin Operasi (TTM) | -575.24% |
| EPS Cair (TTM) | -1.02 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -63.40% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 15.97% |
| Nisbah Semasa (MRQ) | 1.37 |
| Aliran Tunai Operasi (OCF TTM) | -33.95 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -23.55 M |
| Pulangan Atas Aset (ROA TTM) | -44.49% |
| Pulangan Atas Ekuiti (ROE TTM) | -392.69% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | Capricor Therapeutics, Inc. | Menaik | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | 3.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -0.5 |
| Purata Bergerak Teknikal | -1.0 |
| Osilator Teknikal | -0.5 |
| Purata | 0.25 |
|
Capricor Therapeutics Inc is a biotechnology company focused on advancing transformative cell and exosome-based therapeutics to redefine the treatment landscape for rare diseases. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat and prevent a wide range of diseases with targeted delivery. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 16.75% |
| % Dimiliki oleh Institusi | 18.53% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Superstring Capital Management Lp | 30 Sep 2024 | 337,347 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 77.00 (HC Wainwright & Co., 316.44%) | Beli |
| Median | 37.50 (102.81%) | |
| Rendah | 25.00 (Maxim Group, 35.21%) | Beli |
| Purata | 41.67 (125.37%) | |
| Jumlah | 6 Beli | |
| Harga Purata @ Panggilan | 16.10 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Jones Trading | 18 Nov 2024 | 40.00 (116.33%) | Beli | 18.38 |
| Cantor Fitzgerald | 14 Nov 2024 | 30.00 (62.25%) | Beli | 18.49 |
| HC Wainwright & Co. | 14 Nov 2024 | 77.00 (316.44%) | Beli | 18.49 |
| 11 Oct 2024 | 77.00 (316.44%) | Beli | 17.77 | |
| Piper Sandler | 21 Oct 2024 | 35.00 (89.29%) | Beli | 20.57 |
| Maxim Group | 25 Sep 2024 | 25.00 (35.21%) | Beli | 10.34 |
| Oppenheimer | 25 Sep 2024 | 43.00 (132.56%) | Beli | 10.34 |
| 23 Sep 2024 | 15.00 (-18.88%) | Beli | 5.97 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2024 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |